Incisive Genetics
Incisive Genetics Inc. is a Canadian biotech company dedicated to developing innovative gene delivery platforms for genetic therapies. Their mission is to address the critical challenge of effective and safe delivery of gene editing machinery into target tissues, aiming to create potentially curative therapies for serious genetic diseases. They focus on their proprietary Incisive Delivery System™ and OmniaTM platform, which are non-viral delivery methods for CRISPR-based gene therapies, enabling precise, efficient, and safe gene editing solutions.
Industries
Nr. of Employees
small (1-50)
Incisive Genetics
Vancouver, British Columbia, Canada, North America
Products
Patent-pending non-viral LNP delivery platform for CRISPR RNPs
A lipid nanoparticle-based delivery platform designed to encapsulate and deliver pre-formed CRISPR protein–guide RNA complexes (RNPs) for in vivo genome editing applications.
Preclinical CRISPR-based therapeutic candidates
Therapeutic development efforts that pair the LNP delivery platform with active endonuclease proteins and target-specific guide RNAs to create candidate treatments for genetic diseases.
Patent-pending non-viral LNP delivery platform for CRISPR RNPs
A lipid nanoparticle-based delivery platform designed to encapsulate and deliver pre-formed CRISPR protein–guide RNA complexes (RNPs) for in vivo genome editing applications.
Preclinical CRISPR-based therapeutic candidates
Therapeutic development efforts that pair the LNP delivery platform with active endonuclease proteins and target-specific guide RNAs to create candidate treatments for genetic diseases.
Services
In-house platform R&D and preclinical development
Internal research and development of a non-viral LNP delivery platform and conduct of preclinical studies to generate proof-of-concept gene editing data.
In-house platform R&D and preclinical development
Internal research and development of a non-viral LNP delivery platform and conduct of preclinical studies to generate proof-of-concept gene editing data.
Expertise Areas
- Gene delivery platform development
- Lipid nanoparticle formulation for in vivo use
- CRISPR ribonucleoprotein (RNP) delivery
- Preclinical in vivo gene editing studies
Key Technologies
- Lipid nanoparticles (LNPs)
- CRISPR ribonucleoprotein (RNP) delivery
- Guide RNA-based targeting
- Endonuclease protein delivery